Gowthami Morey Arepally, MD

Associate Professor of Medicine
Associate Professor of Pathology
Campus mail Duke Box 3486, Durham, NC 27710
Phone (919) 668-3696
Email address arepa001@mc.duke.edu

Gowthami M. Arepally, M.D. is an Associate Professor in the Division of Hematology at Duke University Medical Center and the Medical Director of Therapeutic Apheresis at Duke.  Her clinical interests are in immune thrombocytopenias, thrombotic disorders, and applications of therapeutic apheresis for immunologic disorders.    Dr. Arepally’s long-standing research program investigates immunoregulatory mechanisms in HIT.  Current laboratory efforts focus on the role of complement activation in the immune pathogenesis of HIT, investigations of protamine/heparin antibodies and development of murine models for studies of the HIT immune response.  Clinical projects include applications of therapeutic apheresis, including development of a multi-site network for investigations of thrombotic microangiopathy, studies of therapeutic plasma exchange for HIT and solid organ transplantation. 

Education and Training

  • Fellow in Hematology-Oncology, Medicine, University of Pennsylvania, 1993 - 1997
  • Chief Medical Resident, Medicine, Emory University, 1992 - 1993
  • Medical Resident, Medicine, Emory University, 1989 - 1992
  • M.D., Vanderbilt University, 1989

Publications

Zheng, Y, Yu, M, Podd, A, Yuan, L, Newman, DK, Wen, R, Arepally, G, and Wang, D. "Critical role for mouse marginal zone B cells in PF4/heparin antibody production." Blood 121, no. 17 (2013): 3484-3492.

PMID
23460609
Full Text

Espinasse, B, Joglekar, M, Valiente, G, and Arepally, GM. "Novel Techniques for Measurement of Variable Sized PF4/H Complexes." November 16, 2012.

Scholars@Duke

Joglekar, M, Qi, R, and Arepally, GM. "PF4/H Complexes Induce Germinal Centers in Vivo." November 16, 2012.

Scholars@Duke

Lee, GM, Welsby, I, Bute, BP, Ortel, TL, and Arepally, GM. "High Incidence of Antibodies to Protamine and Protamine/Heparin Complexes in Patients Undergoing Cardiopulmonary Bypass." November 16, 2012.

Scholars@Duke

Lee, GM, Welsby, I, Bute, BP, Ortel, TL, and Arepally, GM. "High Incidence of Antibodies to Protamine and Protamine/Heparin Complexes in Patients Undergoing Cardiopulmonary Bypass." November 16, 2012.

Scholars@Duke

Arepally, GM. "HIT and run: heparin's unusual immune response." Blood 120, no. 20 (November 15, 2012): 4119-4120.

PMID
23160188
Full Text

Sachais, BS, Litvinov, RI, Yarovoi, SV, Rauova, L, Hinds, JL, Rux, AH, Arepally, GM, Poncz, M, Cuker, A, Weisel, JW, and Cines, DB. "Dynamic antibody-binding properties in the pathogenesis of HIT." Blood 120, no. 5 (August 2, 2012): 1137-1142.

PMID
22577175
Full Text

Kelton, JG, Warkentin, TE, Moore, JC, Arnold, DM, Nazi, I, Arepally, GM, Roach, JM, and Fier, I. "A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins." J Thromb Haemost 10, no. 7 (July 2012): 1446-1449. (Letter)

PMID
22537227
Full Text

Kasthuri, RS, Glover, SL, Jonas, W, McEachron, T, Pawlinski, R, Arepally, GM, Key, NS, and Mackman, N. "PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI." Blood 119, no. 22 (May 31, 2012): 5285-5293.

PMID
22394597
Full Text

Joglekar, MV, Quintana Diez, PM, Marcus, S, Qi, R, Espinasse, B, Wiesner, MR, Pempe, E, Liu, J, Monroe, DM, and Arepally, GM. "Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH)." Thromb Haemost 107, no. 4 (April 2012): 717-725.

PMID
22318669
Full Text

Pages